Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bionano GenomicsSTU:2Y30 64 PB Ratio is 109.90 as of Jul. 19, 2026, which is 7083% above its 10-year median of 1.53. GuruFocus rates STU:2Y30 with a GF Score™ of 64/100 and a GF Value™ of €422.95. The stock has 3 warning signs investors should review. Among 786 Medical Devices & Instruments companies, Bionano Genomics ranks better than 96.31% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-19), Bionano Genomics's share price is €315.84. Bionano Genomics's Book Value per Share for the quarter that ended in Mar. 2026 was €2.87. Hence, Bionano Genomics's PB Ratio of today is 109.90.
The historical rank and industry rank for Bionano Genomics's PB Ratio or its related term are showing as below:
STU:2Y30'
s PB Ratio Range Over the Past 10 Years
Min: 0.14 Med: 1.53 Max: 74.28
Current: 0.35
During the past 10 years, Bionano Genomics's highest PB Ratio was 74.28. The lowest was 0.14. And the median was 1.53.
STU:2Y30's PB Ratio is ranked better than 96.31% of 786
companies
in the Medical Devices & Instruments industry
Industry Median: 2.04
vs STU:2Y30: 0.35
During the past 12 months, Bionano Genomics's average Book Value Per Share Growth Rate was -78.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -79.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -55.90% per year.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Bionano Genomics was 99.60% per year. The lowest was -79.80% per year. And the median was 4.40% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Bionano Genomics PB Ratio Related Terms
Bionano Genomics PB Ratio Historical Data
* Premium members only.
The historical data trend for Bionano Genomics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Bionano Genomics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bionano Genomics PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bionano Genomics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Bionano Genomics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Bionano Genomics (STU:2Y30) has a PB Ratio of 109.90 as of Jul. 19, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Bionano Genomics and its competitors. This is 7083% above median its historical median of 1.53. Over the past decade, Bionano Genomics' PB Ratio has ranged from 0.14 to 74.28. According to the industry distribution chart, Bionano Genomics ranks #29 out of 786 companies in the Medical Devices & Instruments industry, placing it in the top 3.7%.
Is Bionano Genomics' PB Ratio too high?
Bionano Genomics' current PB Ratio of 109.90 is 7083% above median its 10-year median of 1.53. Over the past 10 years, this metric has ranged from a low of 0.14 to a high of 74.28. The Medical Devices & Instruments industry median PB Ratio is 2.04. Bionano Genomics' value of 109.90 is 5287.3% above this industry median. Based on the distribution chart, Bionano Genomics ranks #29 out of 786 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bionano Genomics has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Bionano Genomics' PB Ratio compare to UEEC and CUPR?
According to the Medical Devices & Instruments industry distribution chart, Bionano Genomics ranks #29 out of 786 companies for PB Ratio. This places Bionano Genomics in the top 4% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.04. Bionano Genomics' value of 109.90 is 5287.3% above this benchmark. Historically, Bionano Genomics' own PB Ratio has ranged from 0.14 to 74.28 over the past decade. While the company's 10-year median is 1.53 vs. the industry median of 2.04, Bionano Genomics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.04, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bionano Genomics's current PB Ratio of 109.90 is 5287.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Bionano Genomics and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bionano Genomics's current PB Ratio is 109.90, which is 7083% above median its own 10-year median of 1.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionano Genomics stock overvalued right now?
Bionano Genomics (STU:2Y30) has a current PB Ratio of 109.90. The stock's GF Value™ is €422.95, compared to a current price of €315.84 — trading 25.3% below its estimated fair value. The current PB Ratio is 109.90, which is 7083% above median its 10-year median of 1.53 and 5287.3% above the Medical Devices & Instruments industry median of 2.04. Bionano Genomics' overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Bionano Genomics (STU:2Y30), the current PB Ratio is 109.90 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bionano Genomics (STU:2Y30) Overvalued in 2026?
Based on GuruFocus' analysis, Bionano Genomics stock appears to be undervalued.
The current stock price of €315.84 is trading 25.3% below its estimated GF Value™ of €422.95.
Key valuation signals for STU:2Y30:
PB Ratio: 109.90 (7083% above median its 10-year median of 1.53)
GF Value™: €422.95 vs. price of €315.84 (25.3% below fair value)
Industry Position: 5287.3% above the Medical Devices & Instruments median (#29 of 786)
No single metric tells the full story. See the STU:2Y30 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
64GF Score
Get the complete analysis for STU:2Y30
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2Y30 has been successfully added to your 
